AmitAnandMD

Psychiatry • Boston, MA

Professor, Harvard Medical School. Mass General Brigham.

Join to view full profile

Dr. Anand is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Anand's full profile

Already have an account?

Office
221 Longwood Ave
Boston, MA 02115

Summary

Dr. Anand is Professor of Psychiatry at Harvard Medical School and Director of Translational Clinical Trials at Mass General Brigham. Dr. Anand completed his training from the All India Institute of Medical Sciences, the RANZCP and Yale University. He has conducted the first studies of use of ketamine and glutamatergic modulation and resting state brain connectivity in mood disorders.

Education & Training

Griffin HospitalResidency, Internal Medicine, 1994 - 1994
Yale-New Haven HospitalFellowship, Clinical Neuroscience, 1992 - 1994
Royal Australian and New Zealand College of PsychiatristsFRANZCP, Psychiatry, 1986 - 1991
All India Institute of Medical SciencesClass of 1985

Certifications & Licensure

MA State Medical License 2021 - 2026
OH State Medical License 2012 - 2025
IN State Medical License 2001 - 2017
CT State Medical License 1993 - 2007
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI Start of enrollment: 2011 Nov 01
Completed
Phase 4
Genomics Used to Improve DEpression Decisions Start of enrollment: 2014 Apr 01
Completed
Not Applicable
Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression Start of enrollment: 2016 Jul 01
Completed
Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder Start of enrollment: 2017 Dec 07
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.
Manish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan, Katherine A Collins, Gerard Sanacora
JAMA Network Open. 2024-06-03
9 citations
Focal adhesion is associated with lithium response in bipolar disorder: evidence from a network-based multi-omics analysis.
Vipavee Niemsiri, Sara Brin Rosenthal, Caroline M Nievergelt, Adam X Maihofer, Maria C Marchetto
Molecular Psychiatry. 2024-01-01
3 citations
Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine?
Sanjay J Mathew, Manish K Jha, Amit Anand
JAMA Psychiatry. 2023-12-01

Authored Content

The High Price of Ignoring Disease in the MarginalizedJuly 2020
The High Price of Ignoring Disease in the MarginalizedJuly 2020

Press Mentions

Ketamine Shows Promise for Hard-to-Treat Depression in New StudyMay 26th, 2023
Ketamine Beats Shock Therapy in Easing Tough-to-Treat DepressionMay 25th, 2023
Ketamine as Effective as Electroconvulsive Therapy for Treatment-Resistant DepressionMay 25th, 2023
Join now to see all